Related Experiment Video
Updated: Jul 26, 2025

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
CNK2 promotes cancer cell motility by mediating ARF6 activation downstream of AXL signalling
Guillaume Serwe1,2, David Kachaner1, Jessica Gagnon1,2
1Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.
Abstract:
Cell motility is a critical feature of invasive tumour cells that is governed by complex signal transduction events. Particularly, the underlying mechanisms that bridge extracellular stimuli to the molecular machinery driving motility remain partially understood. Here, we show that the scaffold protein CNK2 promotes cancer cell migration by coupling the pro-metastatic receptor tyrosine kinase AXL to downstream activation of ARF6 GTPase. Mechanistically, AXL signalling induces PI3K-dependent recruitment of CNK2 to the plasma membrane. In turn, CNK2 stimulates ARF6 by associating with cytohesin ARF GEFs and with a novel adaptor protein called SAMD12. ARF6-GTP then controls motile forces by coordinating the respective activation and inhibition of RAC1 and RHOA GTPases. Significantly, genetic ablation of CNK2 or SAMD12 reduces metastasis in a mouse xenograft model. Together, this work identifies CNK2 and its partner SAMD12 as key components of a novel pro-motility pathway in cancer cells, which could be targeted in metastasis.
Insights
The scaffold protein CNK2 promotes cancer cell migration by linking the AXL receptor to ARF6 GTPase activation. Targeting CNK2 and SAMD12 may reduce cancer metastasis.
Area of Science:
- Cell biology
- Molecular oncology
- Signal transduction
Background:
- Cell motility is crucial for invasive tumors, but the mechanisms linking external signals to motility machinery are not fully understood.
- Understanding these pathways is key to developing anti-metastasis therapies.
Purpose of the Study:
- To elucidate the molecular mechanisms by which cancer cells achieve motility.
- To identify novel targets for anti-metastasis therapies.
Main Methods:
- Investigated the role of scaffold protein CNK2 in cancer cell migration.
- Utilized biochemical assays, cell signaling analysis, and a mouse xenograft model.
- Examined the interaction between AXL, CNK2, SAMD12, and GTPases ARF6, RAC1, and RHOA.
Main Results:
- CNK2 couples the AXL receptor tyrosine kinase to ARF6 GTPase activation, promoting cancer cell migration.
- AXL signaling recruits CNK2 to the plasma membrane, where it activates ARF6 via cytohesin ARF GEFs and SAMD12.
- ARF6-GTP regulates cell motility by controlling RAC1 and RHOA GTPase activity.
- Genetic deletion of CNK2 or SAMD12 significantly reduced metastasis in a mouse model.
Conclusions:
- CNK2 and SAMD12 form a novel pro-motility pathway in cancer cells.
- This pathway, involving AXL and ARF6, is critical for cancer cell migration and metastasis.
- CNK2 and SAMD12 represent potential therapeutic targets for inhibiting cancer metastasis.
Related Concept Videos
Cancer Cell Migration through Invadopodia
MAPK Signaling Cascades
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Cytoskeletal Coordination in Cell Migration
Cell Polarization by Rho Proteins
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

